Previous close | 1.4100 |
Open | 1.3600 |
Bid | 1.2800 |
Ask | 1.3400 |
Strike | 80.00 |
Expiry date | 2025-01-17 |
Day's range | 1.3400 - 1.4100 |
Contract range | N/A |
Volume | |
Open interest | 2.94k |
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.